Law & policy

Latest content

Germany’s new government is the last hope for covid IP waiver advocates

A post-Merkel change of approach by the country’s recently agreed traffic light coalition government could change the momentum of TRIPS suspension talks – but don’t bet on it

07 December 2021

Major US and UK SEP/FRAND reviews will have global licensing impact

Biden administration flags revised policy statement that rolls-back on original 2019 version, while the British government begins development of post-Brexit approach

07 December 2021

Huawei knocks out two Chinese patents in global SEP dispute with IP Bridge

Exclusive data shows extent of Japanese firm’s Chinese patent holdings as it heads into a high-stakes rate-setting battle

03 December 2021

Vidal looks all set to lead the USPTO after confident Senate hearing

In a strong display, the Biden administration's choice to lead the agency addressed Section 101 reform and Fintiv discretionary denials, but may have left a hostage to fortune on SEP/FRAND

02 December 2021

USPTO Director nominee Vidal set for Senate hearing tomorrow

President Biden’s pick is likely to face tough questions from senators when she appears in front of the Judiciary Committee on Wednesday

30 November 2021

China patent term extensions create new pitfalls for pharma innovators

Life sciences IP professionals must work closer than ever before with regulatory teams to ensure eligibility for lucrative exclusivity add-ons

30 November 2021

One-on-one with acting USPTO director Drew Hirshfeld

Featured in Special Report 2021 Q4: IP5 insights

29 November 2021

USPTO rejections: post-Alice insights

Featured in Special Report 2021 Q4: IP5 insights

29 November 2021

CNIPA's draft patent examination guidelines: what is coming down the pipeline?

Featured in Special Report 2021 Q4: IP5 insights

29 November 2021

One-on-one with KIPO commissioner Kim Yong Rae

Featured in Special Report 2021 Q4: IP5 insights

29 November 2021

Get unlimited access to all IAM content